Bendamustine Hydrochloride for the Treatment of Relapsed or Refractory Acute Leukemia

Study Title

Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia

Teva Identifier

C18083/2046 | 2010-020768-40

ClinicalTrials.gov Identifier

NCT01088984

Study Status

Completed

Trial Condition(s)

Leukemia

Interventions

Drug: Bendamustine

Study Description

Please refer to ClinicalTrials.gov for a description of the trial
Click for participation criteria and map of study locations
cancer icon for clinical trials

Key Participation Requirements

Gender

Female, Male

Age Range

1 Year to 20 Years

Trial Duration

08/01/2010 - 08/01/2011

Phase

Phase 1/2

Study Type

Interventional